Date: Dec 3 2020
By: Sally Robertson
Chang Yi Wang from United Biomedical Inc Asia in Taipei and colleagues say the vaccine, called UB-612, is the first “multitope” protein-peptide vaccine to be developed against SARS-CoV-2.
UB-612 comprises several components designed to induce high levels of neutralizing antibodies and a broad immune cellular response, including a viral fusion protein, and five synthetic SARS-CoV-2-derived peptides.
Studies in guinea pigs, rats, mice, and rhesus macaques confirmed the immunogenicity and efficacy of UB-612, while toxicity tests in rats indicated the vaccine is safe and well-tolerated.